Jun. 2 at 4:02 PM
$LEGN If any early-stage company claimed thry got 100% ORR in lymphoma with their Invivo CAR-T, the experts and analysts will look at their claim with a dose of scepticism. But If this claim comes from Legend Biotech, the inventor of Carvykti, the highest selling ex vivo CAR-T with functional cure for MM with >5 yr data, you better take a bow and take them seriously.
$JNJ ‘will’ win the bidding war at all cost, be it a specific In Vivo CAR-T program for lymphoma or multiple
Programs or total BO.